What is a stock summary page? Click here for an overview.
Business Description
Theragen Etex Co Ltd
SIC : 111
ISIN : KR7066700006
Compare
Compare
Traded in other countries / regions
066700.Korea Index Membership
KOSDAQ Composite Index IPO Date
2004-05-27Description
Theragen Etex Co Ltd is a Korea-based company mainly engaged in the manufacturing and selling of finished pharmaceutical products and providing genome sequencing services. It also provides healthcare services. The company's operating segments include its Pharmaceutical business and the Healthcare and Genome Analysis Business. A majority of its revenue is generated from the Pharmaceutical Business which involves the manufacturing and sales of specialized and general medicine along with new drug research and development. The Healthcare and Genome Analysis Business involves DNA sequence analysis, RNA mutation genome analysis and decoding, and the distribution of non-prescription drugs for healthcare purposes. Geographically, the company derives its key revenue from the domestic market.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.56 | |||||
| Equity-to-Asset | 0.56 | |||||
| Debt-to-Equity | 0.31 | |||||
| Debt-to-EBITDA | 1.27 | |||||
| Interest Coverage | 4.6 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 2.03 | |||||
| Beneish M-Score | -1.99 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.1 | |||||
| 3-Year FCF Growth Rate | -8.1 | |||||
| 3-Year Book Growth Rate | -28.7 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.73 | |||||
| 9-Day RSI | 55.01 | |||||
| 14-Day RSI | 53.41 | |||||
| 3-1 Month Momentum % | -7.89 | |||||
| 6-1 Month Momentum % | -12.54 | |||||
| 12-1 Month Momentum % | -29.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.27 | |||||
| Quick Ratio | 0.94 | |||||
| Cash Ratio | 0.28 | |||||
| Days Inventory | 81.98 | |||||
| Days Sales Outstanding | 93.04 | |||||
| Days Payable | 62.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | -8.39 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 49.6 | |||||
| Operating Margin % | 4.91 | |||||
| Net Margin % | 11.04 | |||||
| FCF Margin % | -2.73 | |||||
| ROE % | 18.79 | |||||
| ROA % | 10.33 | |||||
| ROIC % | 5.47 | |||||
| 3-Year ROIIC % | -5.57 | |||||
| ROC (Joel Greenblatt) % | 40.04 | |||||
| ROCE % | 19.35 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 3.51 | |||||
| PE Ratio without NRI | 3.31 | |||||
| Price-to-Owner-Earnings | 3.3 | |||||
| PS Ratio | 0.38 | |||||
| PB Ratio | 0.6 | |||||
| Price-to-Tangible-Book | 0.63 | |||||
| Price-to-Operating-Cash-Flow | 10.38 | |||||
| EV-to-EBIT | 4.17 | |||||
| EV-to-EBITDA | 3.54 | |||||
| EV-to-Revenue | 0.58 | |||||
| EV-to-FCF | -20.62 | |||||
| Price-to-GF-Value | 0.49 | |||||
| Price-to-Projected-FCF | 0.81 | |||||
| Price-to-Median-PS-Value | 0.22 | |||||
| Price-to-Graham-Number | 0.31 | |||||
| Earnings Yield (Greenblatt) % | 24.01 | |||||
| FCF Yield % | -6.83 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Theragen Etex Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 249,996.11 | ||
| EPS (TTM) (â‚©) | 889 | ||
| Beta | 0.79 | ||
| 3-Year Sharpe Ratio | -0.58 | ||
| 3-Year Sortino Ratio | -0.7 | ||
| Volatility % | 16.35 | ||
| 14-Day RSI | 53.41 | ||
| 14-Day ATR (â‚©) | 79.856005 | ||
| 20-Day SMA (â‚©) | 3095.5 | ||
| 12-1 Month Momentum % | -29.66 | ||
| 52-Week Range (â‚©) | 2760 - 4580 | ||
| Shares Outstanding (Mil) | 32.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Theragen Etex Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Theragen Etex Co Ltd Stock Events
| Event | Date | Price (â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
Theragen Etex Co Ltd Frequently Asked Questions
What is Theragen Etex Co Ltd(XKRX:066700)'s stock price today?
The current price of XKRX:066700 is â‚©3125.00. The 52 week high of XKRX:066700 is â‚©4580.00 and 52 week low is â‚©2760.00.
When is next earnings date of Theragen Etex Co Ltd(XKRX:066700)?
The next earnings date of Theragen Etex Co Ltd(XKRX:066700) is .
Does Theragen Etex Co Ltd(XKRX:066700) pay dividends? If so, how much?
Theragen Etex Co Ltd(XKRX:066700) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers